Pyridostigmine is a reversible cholinesterase (ChE) inhibitor that is assoc
iated with neurologic dysfunction involving both central and peripheral ner
vous systems. To determine the neurotoxic potential of pyridostigmine, rats
were sacrificed at intervals after drug administration (0.5-1.85 mg/kg, ip
, twice daily for 4 days) and brains examined histologically. ChE inhibitio
n was used as a biomarker of pyridostigmine activity. Using the in situ ter
minal deoxynucleotidyl transferase nick-end labeling of DNA fragments (TUNE
L) method and electron microscopy, apoptotic brain cell death was noted in
cerebral cortex over a dose range of 0.5-1.85 mg/kg and at the higher dose
(1.85 mg/kg), apoptosis was also noted in striatum and hippocampus. These r
esponses were blocked by pretreatment with atropine. Rat cortical cells in
culture also underwent apoptosis when exposed to pyridostigmine (250 mu M f
or 24 hr), indicating that the pyridostigmine can initiate apoptosis, indep
endent of peripheral mechanisms. Pretreatment of cells with atropine (10 mu
M) inhibited pyridostigmine-induced apoptosis, confirming the response was
mediated by muscarinic receptors. Short term treatment of rats with pyrido
stigmine (1.85 mg/kg twice daily for 4 days) induced a prolonged apoptotic
response, which was evident in rat cortex up to 30 days after the last dose
. Active apoptosis persisted, despite recovery of serum ChE activity. These
in vivo and in vitro observations indicate that pyridostigmine can initiat
e a prolonged neurodegeneration. (C) 2000 Intox Press, Inc.